"I am always thankful for the opportunity to work with very inspiring and talented people to develop drugs. “Together we make a difference”. With this vision in mind, I firmly believe in going the extra mile to try to develop the best drugs to help patients."
I joined Genentech in 1992. I enjoy working on interesting projects with talented researchers. Genentech has a very intellectually rich environment. I am very impressed by the consistency in excellence across the whole company. I have had the honor of contributing to the success of the anti-VEGF, anti-IgE and anti-CD20 projects. Being able to help patients makes my job at Genentech very rewarding.
Anal Biochem 463:61-66 (2014).
The focus of my lab is on developing assays for antibody projects. We currently are working on antibody projects for oncology, cancer immunotherapy, infectious disease and ocular indications. We assess activity, antigen binding affinity and Fc receptor binding affinity of antibodies for drug candidate selection. We also measure therapeutic antibody concentrations and detect anti-drug antibodies to support preclinical studies.
In addition, we develop ultra-sensitive assays to quantify endogenous proteins. Currently, we are implementing our patented sensitive immuno-PCR assay method to support biomarker efforts.